Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and using methods

A dosage form and therapeutic agent technology, applied in the field of compounds and pharmaceutical compositions, can solve problems such as glucose-galactose malabsorption

Inactive Publication Date: 2013-12-18
LEXICON PHARM INC
View PDF74 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This is apparently based, at least in part, on the fact that, while humans lacking a functional SGLT2 gene appear to live normally ex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and using methods
  • Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and using methods
  • Compositions comprising inhibitors of sodium-glucose cotransporters 1 and 2 and using methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0264] In vitro human SGLT2 inhibition assay

[0265] Human sodium / glucose cotransporter type 2 (SGLT2; accession number P31639; GI:400337) was cloned into the pIRESpuro2 vector for mammalian expression (construct: HA-SGLT2-pIRESpuro2).

[0266] HEK293 cells were transfected with the human HA-SGLT2-pIRESpuro2 vector, and a large number of stable cell lines were selected in the presence of 0.5 μg / ml puromycin. Human HA-SGLT2 cells were maintained in DMEM medium containing 10% FBS, 1% GPS and 0.5 μg / ml puromycin.

[0267] HEK293 cells expressing human HA-SGLT2 were seeded in 384-well plates (30,000 cells / well) in DMEM medium containing 10% FBS, 1% GPS, and 0.5 μg / ml puromycin, and then incubated at 37 °C, 5%CO 2 Incubate overnight. Then with uptake buffer (140mM NaCl, 2mM KCl, 1mM CaCl 2 , 1 mM MgCl 2 , 10mM HEPES, 5mM Tris, 1mg / ml bovine serum albumin (BSA), pH7.3) to wash the cells. 20 microliters of uptake buffer with or without test compound was added to the cells. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

Description

[0001] This application claims priority to US Provisional Patent Application No. 61 / 430,027, filed January 5, 2011, which is hereby incorporated by reference in its entirety. technical field [0002] The present invention relates to methods for improving the cardiovascular and / or metabolic health of patients, especially patients with type 2 diabetes, and compounds and pharmaceutical compositions that can be used in said methods. Background technique [0003] Type 2 diabetes mellitus (T2DM) is a disorder characterized by elevated serum glucose. One way serum glucose is lowered in patients with this disease is by inhibiting glucose reabsorption in the kidneys. The kidneys play an important role in the overall control of glucose, as glucose is filtered through the glomeruli at a rate of approximately 8 g / h and is almost completely reabsorbed in the proximal tubule through the sodium-glucose cotransporter (SGLT). Komoroski, B. et al., Clin Pharmacol Ther. 85(5):513-9 (2009)....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/16A61K9/20A61K31/335A61P3/10
CPCA61K9/2054A61K9/2077A61K31/335A61K31/7032A61K31/155A61K31/7034A61P13/12A61P3/00A61P3/04A61P3/06A61P43/00A61P7/00A61P9/00A61P9/10A61P9/12A61P3/10A61K9/0053A61K9/20A61K31/351A61K45/06A61K47/38A61K47/00A61K9/16A61K47/02A61K9/1652A61K9/2009A61K31/7028
Inventor 陈金玲纳瑟尔·N·尼亚姆韦亚基尼斯·K·H·昂格
Owner LEXICON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap